Last updated on November 2017

BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease


Brief description of study

BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

Detailed Study Description

Demonstrate whether, in addition to standard of care finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure , a sustained decrease of eGFR ≥ 40% from baseline over at least 4 weeks or renal death

Clinical Study Identifier: TX9143

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Deanna Ferrell RMA CCRC

Northwest Louisiana Nephrology
Shreveport, LA USA
  Connect »